InfectRisk

Is RSV going around in the UK right now?

Should parents be worried? Current RSV (respiratory syncytial virus) activity in the United Kingdom with 12-week trend, especially relevant for infants and adults over 60. Based on UKHSA Dashboard weekly hospital admissions.

Influenza: Low

Low

No. Flu activity in the United Kingdom is currently low and holding steady (as of 26 Apr 2026).

Data window: Week 17 · Apr 20 – Apr 26 · Source: UKHSA (weekly) · Source on summer schedule, weekly data from week 40

Get one free alert when the wave turns in the United Kingdom

We write exactly once: the moment the level goes up. No account, no newsletter. We store your address and the country, nothing else. Every mail has a one click unsubscribe. Privacy

View the last 8 weeks

In week 17 of 2026, Influenza activity in the United Kingdom is classified as low.

Against week 16 the reported value is effectively unchanged (less than 5% difference).

Across the last 8 reported weeks the highest reading was week 10; the level was low in 8 of them.

The last 8 reported weeks

WeekRelativeLevelvs prior week
Week 1742Lowunchanged
Week 1642Low−27%
Week 1557Low+50%
Week 1438Low−37%
Week 1360Low−14%
Week 1270Low+28%
Week 1155Low−45%
Week 10100Low

Relative means the highest of these weekly values is set to 100. Exact incidence rates are in the app.

Is flu going around right now?

Know when it affects you.

This page shows your country. The app shows you.

  • Exact numbers and incidence rates, not just low, moderate, high
  • Your personal risk by age and region
  • A push alert when the wave tips in your region
  • 35 countries and a home-screen widget
Download on the

Current activity

12-week trend · RSV · Relative development · UKHSA hospital admissions
Week 03Week 06Week 09Week 11Week 14
  • InfluenzaLow
    Trend: falling · Week 17
  • COVID-19Low
    Trend: stable · Week 17
  • RSVLow
    Trend: stable · Week 17

What this means

In week 17 of 2026, activity of respiratory syncytial virus (RSV) in the United Kingdom is low. The trend, derived from clinical surveillance, is stable. A slight downward trend has emerged over recent weeks.

Data, context and methodology

The current picture for the United Kingdom is built on the UK Health Security Agency (UKHSA) Dashboard. UKHSA is the national public-health authority for England and publishes weekly NHS England hospital admission rates for influenza and RSV, alongside daily case rate data for COVID-19. We rescale these signals into a consultation-equivalent indicator so the qualitative “low / moderate / high” categories are consistent with how we report other countries.

UKHSA Dashboard

The UKHSA Dashboard is the official public data portal of the UK Health Security Agency. It aggregates surveillance data from NHS England, sentinel primary care networks and laboratory reporting. For our headline level we use the weekly hospital admission rates for flu and RSV, and the daily COVID-19 case rate series.

Hospital admission rates

Flu and RSV are reported as laboratory-confirmed hospital admissions per 100,000 population per week, submitted by NHS England trusts. For COVID-19 the UKHSA Dashboard exposes a daily case rate series, which we aggregate into a weekly rolling mean. Together these give a stable signal of severe respiratory illness pressure that is robust to changes in individual testing behaviour.

Why this source

UKHSA is the authoritative source for England-wide respiratory surveillance and the only one to publish hospital admission rates with national coverage on a weekly cadence. Hospital admissions reflect the load on the healthcare system and update with roughly a one-week lag, while the COVID case-rate series tracks transmission more directly.

Qualitative classification

The “low”, “moderate” and “high” categories follow seasonal reference values and epidemiological thresholds calibrated to match our classifications for other countries. Admission rates and the COVID case-rate series are scaled to consultation-equivalent incidence using pathogen-specific conversion factors derived from typical seasonal peaks. Data refreshes weekly when UKHSA publishes the latest Dashboard update.

Source and seasonal pattern by pathogen

Influenza
The classification is based on the UKHSA Respiratory Surveillance Dashboard, combining hospital admission rates with the RCGP sentinel surveillance network run with the Royal College of General Practitioners. Seasonally, infection waves in the United Kingdom typically peak between December and February; activity is usually markedly lower during the summer months.
COVID-19
The classification is based on the UKHSA Respiratory Surveillance Dashboard, which aggregates COVID-19 hospital admission rates alongside RCGP sentinel indicators. Seasonally, infection waves in the United Kingdom typically peak during winter, with occasional summer waves driven by new variants; activity is usually markedly lower in late spring between waves.
RSV
The classification is based on the UKHSA Respiratory Surveillance Dashboard, which tracks RSV hospital admission rates together with RCGP sentinel surveillance indicators. Seasonally, infection waves in the United Kingdom typically peak between December and February; activity is usually markedly lower in spring and summer.

Frequently asked questions

When is RSV season in the UK?

RSV in the UK typically returns each autumn, rises through November, and peaks between December and February before fading in spring. Intensity varies year to year. UKHSA reports RSV activity weekly within the national influenza and COVID-19 surveillance bulletin, and publishes hospital admission trends for bronchiolitis, which is the clinical entry point for most infant RSV cases.

Who is most at risk from RSV in the UK?

The two main groups at highest risk of severe RSV are infants, especially those under six months and those born prematurely or with heart or lung conditions, and older adults, particularly those aged 75 and above or living with chronic respiratory or cardiac disease. In otherwise healthy adults RSV usually resembles a common cold and resolves within a week or two.

Is there an NHS RSV vaccination programme?

Yes. Since 2024 the NHS offers an RSV vaccine to pregnant women from 28 weeks of pregnancy, which protects infants in the first months of life, and to adults aged 75 to 79. UKHSA monitors the impact of the programme on hospital admissions. For infants not covered by maternal vaccination, the monoclonal antibody nirsevimab is used in specific high-risk groups under JCVI guidance.

How is RSV surveillance conducted in the UK?

UKHSA tracks RSV through the DataMart laboratory reporting system, the SARI-Watch hospital network, and sentinel swabbing in RCGP practices where respiratory samples are tested for multiple pathogens including RSV. Results feed into the UKHSA Dashboard and weekly surveillance reports, which show both the level of activity and how current signals compare to historical baselines.

How is RSV different from flu?

RSV and influenza both cause respiratory infections and circulate together during UK winters, but their risk profiles differ. RSV is the leading cause of bronchiolitis in infants, while flu affects all age groups and carries elevated risk in older adults and people with chronic conditions. Symptoms overlap, and laboratory testing is usually needed to tell them apart reliably.

More situation reports

UKHSA DashboardUKHSA InfluenzaUKHSA RSVUpdated: Sep 1, 2026, 10:08
Published by Dominik Martin · Software engineer and data aggregator· Methodology last reviewed: 07 May 2026· Methodology version 1.2

Data last refreshed: Sep 1, 2026, 10:08. Update cadence: weekly.

This page is not medical advice and does not replace consultation with a healthcare professional. For specific symptoms, please contact a medical professional.

About this page

Published by Renderei Martin GmbH, Berlin. No commercial interest in individual health recommendations. The app is optionally monetised via a freemium subscription.

Content is based exclusively on the linked official surveillance publications. Medical statements are curated against the guidance of RKI, ECDC and WHO.

Methodology enquiries: press@infectrisk.com

About this site and its author